Table of Contents
Chemotherapy Research and Practice
Volume 2011, Article ID 125192, 7 pages
Review Article

Lipoplatin Treatment in Lung and Breast Cancer

1Department of Oncology and Oncohematology, Infermi Hospital, 2 Settembrini Street, 47900 Rimini, Italy
2Department of Oncology, Cervesi Hospital, 1 Beethoven Street, 47841 Cattolica, Italy
3The Cancer Institute of Romagna IRST, 40 Piero Maroncelli Street, 47041 Meldola, Italy

Received 1 September 2010; Accepted 14 December 2010

Academic Editor: Vassilis Georgoulias

Copyright © 2011 Manuela Fantini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic field. Many types of cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compounds were disovered and among them carboplatin and oxaliplatin are the main Cisplatin analogues showing similar clinical efficacy with a safer toxicity profile. Lipoplatin is a new liposomal cisplatin formulation which seems to have these characteristics. Lipoplatin was shown to be effective in NSCLC both in phase 2 and phase 3 trials, with the same response rate of Cisplatin, a comparable overall survival but less toxicity. A new protocol aiming to elucidate the double capacity of Lipoplatin to act as a chemotherapeutic and angiogenetic agent in triple-negative breast cancer patients is upcoming.